CERENOME, INC. CNSY
Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system ("CNS") cancers. CNSide Diagnostics, LLC ("CNSide Diagnostics") is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. In radiopharmaceuticals, our lead candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma ("GBM"), leptomeningeal metastases ("LM"), and pediatric brain cancers ("PBC") by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery ("CED") and intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere ("188RNL-BAM") is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial injection.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $5.8M | $4.9M | — | — | — | — | $1.0M | $2.7M | $4.7M |
| Cost of revenue | — | — | — | — | — | — | — | $1.1M | $1.3M | $2.7M |
| Gross profit | — | — | — | — | — | — | — | -$148.0K | $146.0K | $1.9M |
| R&D | $8.4M | $10.6M | $9.7M | $9.7M | — | $2.7M | $5.4M | $5.5M | $5.1M | $16.2M |
| SG&A | $12.1M | $9.9M | $8.5M | $10.2M | $6.9M | $6.4M | $5.3M | $5.6M | $6.7M | $8.6M |
| Total operating expenses | $20.5M | $20.5M | $18.2M | $19.9M | $12.5M | $9.9M | $10.7M | $11.7M | $14.8M | $28.4M |
| Operating income | -$15.3M | -$14.7M | -$13.3M | -$19.7M | -$12.5M | -$9.6M | -$3.7M | -$8.8M | -$11.1M | -$19.7M |
| Interest expense | $548.0K | $179.0K | $395.0K | $711.0K | $932.0K | $1.1M | $1.9M | $1.9M | $2.0M | $2.6M |
| Pre-tax income | -$22.4M | -$13.0M | -$13.3M | -$20.3M | -$13.4M | -$8.2M | -$10.9M | -$12.6M | -$22.7M | -$22.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$22.4M | -$13.0M | -$13.3M | -$20.3M | -$13.4M | -$8.2M | -$10.9M | -$12.6M | -$22.7M | -$22.0M |
| EPS, basic | -0.29 | -1.95 | -4.24 | -11.58 | -1.11 | — | — | — | — | — |
| EPS, diluted | -0.29 | -2.34 | -4.24 | -11.58 | -1.11 | -1.86 | -8.27 | -86.98 | -411.60 | -1.28 |
| Shares, diluted (wtd. avg.) | 77.8M | 7.7M | 3.1M | 1.8M | 12.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.3M | $76.0K | $8.6M | $18.1M | $18.4M | $8.3M | $17.6M | $5.3M | $9.6M | $12.6M |
| Short-term investments | $4.4M | $3.5M | — | — | — | — | — | — | — | — |
| Receivables | — | — | — | — | — | $0 | $1.2M | $178.0K | $145.0K | $1.2M |
| Inventory | — | — | — | — | — | — | $107.0K | $107.0K | $3.2M | $3.7M |
| Total current assets | $15.2M | $5.3M | $9.8M | $21.8M | $19.7M | $9.2M | $19.8M | $9.6M | $14.9M | $18.7M |
| Property, plant and equipment | $257.0K | $448.0K | $906.0K | $1.3M | $1.5M | $1.8M | $2.2M | $2.3M | $3.1M | $1.2M |
| Goodwill | $372.0K | $372.0K | $372.0K | $372.0K | $372.0K | $372.0K | $372.0K | $372.0K | $3.9M | $3.9M |
| Other intangibles | $333.0K | $469.0K | $42.0K | — | — | — | — | $6.0M | $7.2M | $8.4M |
| Total assets | $16.3M | $6.6M | $11.4M | $23.9M | $22.0M | $12.1M | $23.2M | $24.0M | $31.6M | $34.6M |
| Accounts payable | $3.3M | $9.5M | $4.8M | $8.4M | $2.6M | $789.0K | $327.0K | $721.0K | $1.3M | $1.3M |
| Short-term debt | — | — | $4.0M | $1.6M | $1.6M | $6.3M | $11.1M | $14.2M | $13.6M | $6.6M |
| Total current liabilities | $12.3M | $15.6M | $10.7M | $11.9M | $5.9M | $8.5M | $14.5M | $17.6M | $18.4M | $12.5M |
| Long-term debt | — | — | — | $3.8M | $5.0M | — | — | — | — | — |
| Total liabilities | $12.3M | $15.6M | $12.7M | $17.4M | $11.1M | $9.1M | $22.1M | $18.8M | $18.6M | $23.6M |
| Retained earnings | -$515.9M | -$493.5M | -$480.5M | -$467.2M | -$446.9M | -$433.5M | -$425.3M | -$414.4M | -$401.7M | -$379.1M |
| Total equity | $4.0M | -$8.9M | -$1.3M | $6.4M | $10.8M | $3.0M | $1.2M | $5.2M | $13.0M | $11.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.8M | -$10.6M | -$12.9M | -$13.0M | -$10.3M | -$8.4M | -$5.9M | -$12.0M | -$18.1M | -$19.5M |
| Depreciation and amortisation | $445.0K | $872.0K | $628.0K | $619.0K | $395.0K | $366.0K | $896.0K | $2.0M | $2.2M | $1.2M |
| Stock-based compensation | $1.5M | $550.0K | $569.0K | $606.0K | $606.0K | $247.0K | $127.0K | $355.0K | $753.0K | $1.1M |
| Capital expenditure | $67.0K | $146.0K | $160.0K | — | — | — | $67.0K | $133.0K | $295.0K | $67.0K |
| Investing cash flow | -$854.0K | -$4.1M | -$160.0K | -$759.0K | -$82.0K | -$493.0K | $5.6M | -$133.0K | -$1.4M | $64.0K |
| Financing cash flow | $30.3M | $6.2M | $3.4M | $13.5M | $20.4M | -$319.0K | $12.6M | $7.2M | $16.8M | $17.6M |
| Buybacks | — | $374.0K | $126.0K | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-104258.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $2.7M | $1.0M | — | — | — | — | $4.9M | $5.8M | $5.2M |
| Gross profit | $1.9M | $146.0K | -$148.0K | — | — | — | — | — | — | — |
| Net income | -$22.0M | -$22.7M | -$12.6M | -$10.9M | -$8.2M | -$13.4M | -$20.3M | -$13.3M | -$13.0M | -$22.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed Item 5.03
- Other event Item 8.01
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.42B | 36.4x | 11.2% |
| MMM | 3M CO | $89.11B | 28.8x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.06B | 23.5x | 19.9% |
| BDX | BECTON DICKINSON & CO | $53.49B | 33.7x | 8.2% |
| RMD | RESMED INC | $36.52B | 24.3x | 9.9% |
| DXCM | DEXCOM INC | $29.65B | 37.6x | 15.6% |
| MDLN | Medline Inc. | $28.86B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.78B | 58.1x | 6.3% |